Loading stock data…
Zoetis Inc. (ZTS)
$75.81-0.48 (-0.63%)
Pre-Market$75.34-0.47 (-0.62%)· Last close Sep 4
Zoetis Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zoetis Inc. in the Healthcare sector is trading at $75.81 with a market capitalization of $30.0B. Wall Street consensus targets $96.00 (15 analysts), implying a +26.6% move over the next 12 months. The stock is currently near its 52-week low of $71.00, remaining 25.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +26.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.47B↑ | $2.26B↓ | $2.39B↓ | $2.40B↓ | $2.47B |
| Gross Profit | $1.79B↑ | $1.62B↓ | $1.68B↓ | $1.72B↓ | $1.81B |
| Operating Income | $999.00M↑ | $822.00M↓ | $826.00M↓ | $936.00M↓ | $997.00M |
| Net Income | $691.00M↑ | $601.00M↓ | $603.00M↓ | $721.00M↓ | $726.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the Uni...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.02B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.85
Beta
Defensive asset. Lower volatility than the S&P 500.
0.73
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.76%
ROE
Elite ROE. Management converts capital into profit efficiently.
83.10%
Volume
Today's trading volume
3.99M
Recent News
Is Zoetis Stock Underperforming the S&P 500?
Zoetis has significantly lagged the broader market over the past year, while analysts remain cautiously optimistic about its outlook.
Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared
The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi
Phibro Animal Health Corporation Q4 2026 Earnings Call Summary
Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product sales, Simparica Trio received Emergency Use Authorization to treat New World screwworm infestations in dogs and puppies. The treatment […]